recommendation. MICs obtained were significantly raised with meropenem and sanfetrinem and to a lesser extent with benzylpenicillin when using media E , F and G (all containing cysteine).
When sanfetrinem MIC data for media with and without the addition of L-cysteine were compared statistically (paired t-test) a P value of 0.0001 was obtained, indicating that there was a significant statistical difference. When medium D (NCCLS reference medium) and medium A (BSA C Working Party recommendation) were compared there was no statistical difference in results (P 0.4294). A similar pattern of results was obtained for N . m eningitidis. It is also worthy of note that all strains grew on medium A , whereas one clinical isolate of N . gonorrhoeae failed to grow on the NCCLS recommended media (F and G ).
These data suggest that Iso-Sensitest agar supplemented with 20 mg/L NA D and 5% whole horse blood would be appropriate for sensitivity testing compounds affected by the presence of L-cysteine. Previous data published from this department have also shown that this medium is suitable for testing other fastidious organisms such as Streptococcus pneum oniae and H aem ophilus influenz ae.
3
The results from a recent BSA C questionnaire have shown that there is a general consensus that there is a need to standardize the testing of fastidious organisms. These data suggest that supplemented Iso-Sensitest agar, the medium chosen by the BSA C Working Party on antibiotic sensitivity testing, would be appropriate and that MIC results obtained with this medium would be comparable to those obtained on the NCCLS recommended media.
Figure.
Mode MIC of sanfetrinem, meropenem, spectinomycin, benzylpenicillin, cefixime and ciprofloxacin against 11 strains of N . gonorrhoeae determined on seven different media. , sanfetrinem; , meropenem; , spectinomycin; , benzylpenicillin; , cefixime; , ciprofloxacin. 1 The failure of antibiotics has been suggested to be based upon (i) slower growth of bacteria within the abscess environment, (ii) low pH of pus which inactivates certain antibiotics or (iii) inability of the drug to penetrate abscess fluid.
2 The pharmacokinetics and pharmacodynamics of antimicrobials in abscess fluid have not been well studied in humans. The degree and rapidity of antimicrobial penetration into abscess fluid may influence the identification of microbial pathogens and the optimal treatment of these infections. The following study characterizes the penetration of a third-generation cephalosporin, ceftizoxime, into abscess fluids in patients, including those with brain abscesses. The study was approved by the Committee on H uman R esearch at the U niversity of California San Francisco. Patients receiving intravenous ceftizoxime requiring either percutaneous or surgical drainage of abscess fluid were identified. Samples of abscess fluid were taken, and antimicrobial history (patients A -F all received concomitant metronidazole with ceftizoxime; patients G and H were treated with ceftizoxime monotherapy), blood chemistries and microbiology reports were documented. O nce sampled, abscess fluid was stored at 70°C until performance of the assay. D etermination of ceftizoxime concentrations in abscess fluid was performed via reversed-phase high pressure liquid chromatography, as previously described.
3 A erobic and anaerobic bacteriological cultures were performed according to routine laboratory methods by the clinical microbiology laboratory.
Ceftizoxime was found to penetrate readily into abscess fluid, with levels ranging from 2 to 30 mg/L (Table) . The highest concentrations were noted in patients receiving 2.0 g doses (patients G and H ) or associated with more long-term therapy (patients C, E , F and H ). Penetration into abscess fluid was confirmed as early as 10-15 min after administration of a single iv dose. Immediate penetration similarly was seen in two patients with brain abscesses. O ne patient (patient G ) had a level of 2.8 mg/L 0.5 h after a single dose, which increased to 30.1 mg/L 0.83 
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